RxDoctor Payments Data

Vladimir Curkovic, MD

Cardiovascular Disease · Zephyrhills, FLNPI 1659384964

Payments from drug & device makers

$12,735in general payments, 2019–2025

Across 465 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$2K
  • Biotronik Inc.$806
  • Boston Scientific$748
  • Amgen$710
  • Boehringer Ingelheim$682
  • Novartis$647
  • plus $7K from 39 others

What the payments were for

  • Travel & lodging$4363%
  • Food & beverage$11,86193%
  • Education$4393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,735 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$705,191
Medicare patients
1,001
Services billed
6,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban836$951,196
XareltoRivaroxaban185$194,243
EntrestoSacubitril/Valsartan162$172,583
BrilintaTicagrelor70$68,196
Repatha SureclickEvolocumab35$30,614
JardianceEmpagliflozin32$29,865
Repatha SyringeEvolocumab23$18,894
Metoprolol Succinate1,195$11,444
Amiodarone Hcl518$10,945
Ranolazine ErRanolazine91$7,170
Dabigatran EtexilateDabigatran Etexilate Mesylate18$5,974
Isosorbide Mononitrate ErIsosorbide Mononitrate489$5,059
Digoxin58$4,895
ClopidogrelClopidogrel Bisulfate449$4,779
Carvedilol566$4,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$476$951,196836 claims
Johnson & JohnsonXarelto$614$194,243185 claims
NovartisEntresto$647$172,583162 claims
AstraZenecaBrilinta$381$68,19670 claims
Boehringer IngelheimJardiance$682$29,86532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →